Genetic Contribution to End-Stage Cardiomyopathy Requiring Heart Transplantation.
Yuri KimOddný Brattberg GunnarsdóttirAnissa ViveirosDaniel ReichartDaniel QuiatJon A L WillcoxHao ZhangHuachen ChenJustin J CurranDaniel H KimSimon UrschelBarbara McDonoughJoshua M GorhamSteven R DePalmaJonathan G SeidmanChristine E SeidmanGavin Y OuditPublished in: Circulation. Genomic and precision medicine (2023)
Pathogenic variants and viral myocarditis were identified in 45.9% of patients with unexplained end-stage cardiomyopathy. Damaging gene variants are significantly more frequent among transplant compared with patients with ambulatory cardiomyopathy. Genetic analyses can help define cause of end-stage cardiomyopathy guide management and risk stratification of patients and family members.